Polarean Imaging plc.’s technology is for research use only

Polarean adds third trial site to late-stage study of its lung MRI scan technology

MRI scans generally aren’t very useful in assessing lung function, but Polarean’s 129Xe gas is trying to change that. Polarean Imaging Plc (LON:POLX) is adding a third clinical trial site to the phase III study of its hyperpolarised 129-Xenon (129Xe) gas magnetic resonance imaging (MRI) technology. MRI scans generally aren't much use when assessing lung function, but Polarean has developed a way in which a small amount of inert gas can change that.

learn more

Meet Polarean at the ATS Annual International Conference in Dallas this May

Polarean will be exhibiting at the ATS 115th Annual Conference in Dallas, May 19–21, 2019.
Please visit us at booth # 2717 to learn more about Polarean’s latest technical advances in hyperpolarized gas MRI technology and updates on FDA clinical trials. We look forward to meeting you in Dallas.

learn more